Conceptus(R) to Participate in Four Investor Conferences
May 09 2012 - 5:49PM
Conceptus, Inc. (Nasdaq:CPTS), developer of the
Essure® procedure, the first and only proven non-incisional
permanent birth control method available, announced today that
company management is planning to participate in the following
investor conferences:
- The Bank of America Merrill Lynch 2012 Health Care Conference
on Tuesday, May 15, 2012, in Las Vegas, Nevada. A live webcast of
the company presentation will take place at 8:40 a.m. Pacific time
and will be available on the company's website at
www.conceptus.com.
- The GARP Research and Securities Company Investor Conference on
Wednesday, May 23, 2012, in Baltimore, Maryland. There will be
no webcast presentation.
- The 9th Annual Craig-Hallum Institutional Investor Conference
on Wednesday, May 30, 2012, in Minneapolis, Minnesota. There
will be no webcast presentation.
- The Jefferies 2012 Global Healthcare Conference on Tuesday,
June 5, 2012, in New York City, New York. A live webcast of
the company presentation will take place at 8:00 a.m. Eastern time
and will be available on the company's website at
www.conceptus.com.
When accessing the live webcasts on www.conceptus.com, select
"Investors" then select "Events and Presentations." Archived
replays will be available following the live presentations.
About the Essure® Procedure
The Essure procedure, FDA approved since 2002, is the first
permanent birth control method that can be performed in the comfort
of a physician's office in less than 10 minutes (average
hysteroscopic time) without hormones, cutting, burning or the risks
associated with general anesthesia or tubal ligation. Soft,
flexible inserts are placed in a woman's fallopian tubes through
the cervix without incisions. Over the next three months, the body
forms a natural barrier around and through the inserts to prevent
sperm from reaching the egg. Three months after the Essure
procedure, a doctor is able to perform an Essure Confirmation Test
to confirm that the inserts are properly placed and that the
fallopian tubes are fully blocked, allowing the patient to rely
upon Essure for permanent birth control.
The Essure procedure is 99.83% effective based on five years of
follow up with zero pregnancies reported in clinical trials, making
it the most effective form of permanent birth control on the
market. Essure's 10-year commercial data tracks closely with
its five-year clinical results, and Essure has been proven and
trusted by physicians since 2002. The Essure procedure is
covered in the U.S. by most public and private insurance plans and
more than 625,000 women worldwide have undergone the
procedure.
About Conceptus®, Inc.
Conceptus, Inc. is a leader in the design, development and
marketing of innovative solutions in women's healthcare. The
Company manufactures and markets the Essure procedure. The
Essure procedure is available in the United States, Europe,
Australia, New Zealand, Canada, Mexico, Central and South America
and the Middle East.
Please visit www.essure.com for more information on the Essure
procedure. Patients may call the Essure Information Center at
1-877-ESSURE-1 with questions or to find a physician in their
area.
The Conceptus, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=7961
© 2012 Conceptus, Inc.— All rights reserved.
CONTACT: Investor and Public Relations Contact:
Cindy Klimstra
(650) 962-4032
cindy_klimstra@conceptus.com
Conceptus, Inc. (MM) (NASDAQ:CPTS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Conceptus, Inc. (MM) (NASDAQ:CPTS)
Historical Stock Chart
From Jul 2023 to Jul 2024